Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03988088 · ClinicalTrials.gov registry record · Phase 1
A Study of Lasmiditan (LY573144) in Children Aged 6 to 17 With Migraine
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT03988088 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 18 participants.
The verdict
NCT03988088, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of the study is the measure the levels of lasmiditan in the body of children aged 6 to 17 with migraine. The study also will also examine the safety and tolerability of lasmiditan in children aged 6 to 17 with migraine. The study will last about 6 weeks, and includes 4 visits.
Interventions
- DRUG Lasmiditan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2019-07-22 |
| Est. Completion | 2020-02-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03988088
The ClinicalTrials.gov registry entry for NCT03988088 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lasmiditan is the first listed.
NCT03988088 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03988088 about?
NCT03988088 is a clinical study titled "A Study of Lasmiditan (LY573144) in Children Aged 6 to 17 With Migraine". The purpose of the study is the measure the levels of lasmiditan in the body of children aged 6 to 17 with migraine. The study also will also examine the safety and tolerability of lasmiditan in children aged 6 to 17 with migraine. The study will last about 6 weeks, and includes 4 visits.
What is the current status of trial NCT03988088?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2019-07-22. Estimated completion is 2020-02-24.
What interventions are being tested in trial NCT03988088?
The interventions under investigation include: Lasmiditan (DRUG).
Who is sponsoring clinical trial NCT03988088?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.